Food and Drug Administration (FDA)-approved molecular targeted therapy for ameloblastomas include drugs able to inhibit the functions of mutated BRAF and mitogen-activated protein kinase kinase (MEK) [63,64]. Here, WNK2 is linked to ameloblastoma.